Home The Word Brain My Amedeo FAQ Privacy About   


Explore this week’s CC Journal Club

90‑sec video • 4‑min audio • paper abstracts


  HIV Infection

  Free Subscription


Articles published in J Acquir Immune Defic Syndr

Retrieve available abstracts of 297 articles:
HTML format



Single Articles


    May 2025
  1. ATUJUNA M, Nyamaizi AM, Duby Z, Minnis A, et al
    Men's Voices on Long-Acting Pre-Exposure Prophylaxis Delivery Modalities: Acceptability and Preferences Among Cisgender Men and Men Who Have Sex With Men in South Africa.
    J Acquir Immune Defic Syndr. 2025;99:55-63.
    PubMed     Abstract available


  2. WANG H, Delnoij M, Zimmermann HML, Jonas KJ, et al
    The Disparities of PrEP Adherence Among Men Who Have Sex With Men Between the Global South and the Global North: An Updated Determinantal Global Meta-Analysis.
    J Acquir Immune Defic Syndr. 2025;99:1-8.
    PubMed     Abstract available


    April 2025
  3. HUMPHRIES DL, Audet CM, Balasubramanian BA, Benbow N, et al
    Building the Road to End the HIV Epidemic Through Coordinating and Capacity-Building Hubs to Enhance the Science of HIV Implementation REsearch (CHESHIRE): Reflections and Directions: Erratum.
    J Acquir Immune Defic Syndr. 2025 Apr 18. doi: 10.1097/QAI.0000000000003684.
    PubMed    


  4. MAROTTA PL, Humphries D, Escudero D, Katz DA, et al
    Strengthening the US Health Workforce to End the HIV Epidemic: Lessons Learned From 11 EHE Jurisdictions: Erratum.
    J Acquir Immune Defic Syndr. 2025 Apr 18. doi: 10.1097/QAI.0000000000003683.
    PubMed    


  5. NDONGO FA, Tejiokem MC, Penda CI, Ndiang ST, et al
    IMMUNOLOGICAL AND VIROLOGIC OUTCOMES WITHIN TEN YEARS OF COMBINED ANTIRETROVIRAL THERAPY INITIATED BEFORE ONE YEAR OF AGE IN CAMEROONIAN CHILDREN WITH PERINATAL HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003687.
    PubMed     Abstract available


  6. NAMPOTA-NKOMBA N, Buchwald A, Nyirenda OM, Mkandawire FA, et al
    Association between Maternal HIV and Adverse Birth Outcomes in the Era of Universal Antiretroviral Therapy in Malawi.
    J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003685.
    PubMed     Abstract available


  7. CRANE HM, Ruderman SA, Nance RM, Drumright LN, et al
    Approaches to optimally target frailty screening among people with HIV in clinical care: findings from the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS).
    J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003688.
    PubMed     Abstract available


  8. JONES J, Siegler AJ, Glick JL, Lucas IL, et al
    Brief Report: Potential Gains in PrEP Coverage and Effect on Racial Disparities After Introduction of On-Demand and Long-Acting Injectable PrEP: Preferences of Men Who Have Sex With Men in the United States, 2021-2022.
    J Acquir Immune Defic Syndr. 2025;98:429-433.
    PubMed     Abstract available


  9. SIRIBELLI A, Diotallevi S, Galli L, Muccini C, et al
    Non-liver Malignancies as Main Cause of Mortality After HCV Eradication Among People Living With HIV: Erratum.
    J Acquir Immune Defic Syndr. 2025;98:e16.
    PubMed    


  10. DONOSO VA, Chandra S, Zamantakis A, Kassanits J, et al
    Two Pilots of an Implementation Science Training Program for HIV Prevention and Care Service Providers: Lessons Learned and Future Directions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  11. KHOSROPOUR CM, Means AR, Kerani RP, Murphy EM, et al
    Developing Implementation Science Capacity Within Health Departments Located in Ending the HIV Epidemic Priority Areas.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  12. GARNER BR, Bouris A, Charlebois ED, Li DH, et al
    The Strategies Timeline and Activities Reporting Tables: Improving HIV Care by Improving the Reporting of Implementation Strategies.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  13. KATOMSKI AS, Pachicano AM, Zamantakis A, Benbow ND, et al
    Policymaker Perspectives on Implementation Determinants of Rapid ART and Same-Day PrEP in Seven Priority Jurisdictions for Ending the HIV Epidemic: A Multisite Qualitative Study.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  14. MAROTTA PL, Humphries D, Escudero D, Katz DA, et al
    Strengthening the US Health Workforce to End the HIV Epidemic: Lessons Learned From 11 Ending the HIV Epidemic Jurisdictions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  15. MCCOY K, Mantell JE, Deiss R, Liu A, et al
    Pre-Exposure Prophylaxis Awareness and Demand Creation: Overlooked Populations and Opportunities to Move Forward.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  16. MANTELL JE, Bauman LJ, Bonett S, Buchbinder S, et al
    Innovation in Providing Equitable Pre-exposure Prophylaxis Services in the United States: Expanding Access in Nontraditional Settings.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  17. BROWN LL, Batchelder AW, Gondre-Lewis MC, Willie TC, et al
    Innovations to Address Unmet Behavioral Health Needs in National Ending the HIV Epidemic Priority Jurisdictions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  18. JONES JL, Schwartz S, Kassanits JE, Pyra M, et al
    Rapid ART, Rapid PrEP, and Status Neutral Implementation in Ryan White-Funded Clinics: Results From a Multisite Survey.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  19. BELTRAN RM, Katomski AS, Bonett S, Cianelli R, et al
    Lessons Learned From Engaging Healthcare Providers in Research on Implementation of HIV Preexposure Prophylaxis.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  20. GIGUERE R, Mmeje O, Patel VV, Felsen UR, et al
    Defining Study Populations in HIV Prevention Implementation Science Studies: A Case Comparison of 3 Ending the HIV Epidemic Projects.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  21. OGUNBAJO A, Martinez O, Akiyama M, Dombrowski JC, et al
    Implementation Science Approaches to Addressing the Social and Structural Determinants of Health of Criminal-Legal Involved People Living With HIV to Improve HIV Care Outcomes.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  22. NOWOTNY KM, Culbertson K, Akiyama MJ, Callen E, et al
    Integrating People With Lived Experience of Carceral System Involvement Into Research: Lessons Learned From Ending the HIV Epidemic Research Teams.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  23. RODRIGUEZ-DIAZ CE, Jaramillo J, Santiago-Rivera Y, Harkness A, et al
    Language Justice in Implementation Science: Experiences Working With Latinxs to End the HIV Epidemic.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  24. SHAH HS, Serrano PA, Rodriguez-Diaz CE, Page KR, et al
    Not a Monolith: Regional HIV Implementation Science Lessons With Latino/a/x Populations.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  25. MACAPAGAL K, Stoner MCD, Guss CE, Sukhija-Cohen AC, et al
    Lessons Learned in Engaging Adolescents and Young Adults to End the US HIV Epidemic.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  26. RODRIGUEZ-DIAZ CE, Kopeka MP, Tun W, Santiago-Rodriguez EI, et al
    Communities Started the End of the HIV Epidemic: Experiences With and Recommendations for Conducting Community-Engaged HIV Implementation Research.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  27. LANZI RG, Varley A, Ott C, Wolfner C, et al
    Implementation Science Methods, Challenges, and Associated Solutions: Transportable Lessons Learned and Best Practices From the Second National Meeting for Research and Community Collaboration Toward Ending the HIV Epidemic in the United States.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  28. SCHWARTZ S, Benbow N, Brewer RA, Beres LK, et al
    Generating Evidence for Effective HIV Implementation at Scale: The Value and Feasibility of a Network for Implementation Science in HIV.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  29. SIMON CL, Carlisle NA, Kermani M, Cole C, et al
    Community Engagement to Empowerment: Emphasizing Relationships, Process, Resources, and Context to Strengthen Community Engagement in EHE Research Partnerships.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  30. BERES LK, Harkness A, Corcoran J, Datar R, et al
    Improving Community-Engaged Implementation Science: Perspectives From "Ending the HIV Epidemic" Supplement Award Cases in the United States.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  31. DATAR R, Schwartz S, Gomez W, Katz DA, et al
    Community-Engaged Research in HIV Implementation Science: Characterizing Academic and Community Partnerships in the "Ending the HIV Epidemic" Supplement Awards.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  32. HUMPHRIES DL, Audet CM, Balasubramanian BA, Benbow N, et al
    Building the Road to End the HIV Epidemic Through Coordinating and Capacity-Building Hubs to Enhance the Science of HIV Implementation REsearch (CHESHIRE): Reflections and Directions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  33. GORDON C, Koenig LJ, Psihopaidas D, Refsland E, et al
    Leveraging Implementation Science to End the HIV Epidemic in the United States: Progress and Opportunities for Federal Agencies.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  34. LI DH, Gaines Lanzi R, Pyra M
    Progress and Priorities to End the HIV Epidemic by 2030: Combined Lessons From 120 US Implementation Research Projects.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  35. SETIA WIRAWAN GB, Navin KS, Lila Wulandari LP, Boettiger D, et al
    Retention and viral suppression with differentiated time or space for adolescent and young adult HIV care: a systematic review and meta-analysis.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003681.
    PubMed     Abstract available


  36. MILICIC A, Wilson S, Javandel S, Allen IE, et al
    Plasma Inflammatory Biomarkers Link to Worse Cognition Among Africans with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003679.
    PubMed     Abstract available


  37. ZHU W, Huang YA, Kourtis AP, Neblett-Fanfair R, et al
    Trends in HIV preexposure prophylaxis use before and after launch of the Ending the HIV Epidemic in the U.S. initiative, 2016-2023.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003674.
    PubMed     Abstract available


  38. CHEN Y, Montano MA, Naik P, Thuo N, et al
    Incremental cost of pre- and post-exposure prophylaxis service provision via an online pharmacy in Kenya.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003680.
    PubMed     Abstract available


  39. WALL KM, Sullivan P, Shrestha RK, Dana R, et al
    Cost and cost-effectiveness of online recruitment to increase HIV self-testing among Black and Hispanic/Latino men who have sex with men in the United States, 2020-2021.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003666.
    PubMed     Abstract available


  40. MOROZOVA O, Conroy K, Riabokon S, Germanovich M, et al
    HIV Viral Rebound on Dolutegravir, Lopinavir and Efavirenz: National Program Data Analysis from Ukraine.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003676.
    PubMed     Abstract available


  41. BUNTING SR, Feinstein BA, Wilson A, Rivera J, et al
    Preferences for PrEP Implementation and Engagement in the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum among Patients Receiving Psychiatric Care in an Ending the HIV Epidemic Priority County.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003675.
    PubMed     Abstract available


  42. IZQUIERDO R, Vallejo A, Suarez-Garcia I, Martin-Hondarza A, et al
    Markers of inflammation and immune dysfunction and non-AIDS cancer risk in adults with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003667.
    PubMed     Abstract available


  43. JAROLIMOVA J, Yan J, Govere S, Shezi S, et al
    Sexually transmitted infection testing integrated with HIV prevention and contraceptive services in hair salons in urban South Africa.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003677.
    PubMed     Abstract available


  44. DUNK CE, Powis KM, Legbedze J, Sun S, et al
    Low placental growth factor levels mid-gestation predict small for gestational age in pregnant women with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003672.
    PubMed     Abstract available


  45. FISHER SA, Jao J, Yee LM, Serghides L, et al
    Fatty acid signatures in people with HIV: association with adverse pregnancy outcomes and offspring anthropometrics.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003665.
    PubMed     Abstract available


  46. ELBUR AI, Mirzazadeh A, Tate M, Suprasert B, et al
    HIV Incidence among People Who Inject Drugs, San Francisco, 2022.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003673.
    PubMed     Abstract available


  47. EDWARDS KA, Smith KJ, Jones KF, Bair MJ, et al
    Cost-Effectiveness of a Tailored Pain Self-Management Intervention Compared to Enhanced Usual Care Among People with HIV and Chronic Pain: An Economic Evaluation.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003671.
    PubMed     Abstract available


  48. SHARMA A, Hoover DR, Shi Q, Daubert E, et al
    Poor Sleep Quality is Associated with Frailty Among Women with and without HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003668.
    PubMed     Abstract available


  49. GOYAL R, Honerkamp-Smith G, Wells A, Little SJ, et al
    Predictive models to identify individuals with HIV at risk of unsuppressed viral load using routine public health data.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003670.
    PubMed     Abstract available


  50. REMERA E, Chammartin F, Nsanzimana S, Malamba SS, et al
    Factors associated with recent HIV infections among newly HIV diagnosed in Rwanda.
    J Acquir Immune Defic Syndr. 2025 Apr 2. doi: 10.1097/QAI.0000000000003669.
    PubMed     Abstract available


  51. WANG RJ, Kunisaki KM, Morris A, Drummond MB, et al
    Brief Report: The Implications of Removing Race From Interpretation of Pulmonary Function Among Persons With or Without HIV.
    J Acquir Immune Defic Syndr. 2025;98:395-400.
    PubMed     Abstract available


  52. TARAMASSO L, Rossotti R, Tavelli A, Santoro MM, et al
    Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort.
    J Acquir Immune Defic Syndr. 2025;98:352-356.
    PubMed     Abstract available


  53. THEODORE DA, Neradilek M, Gillespie K, Edupuganti S, et al
    Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085.
    J Acquir Immune Defic Syndr. 2025;98:340-345.
    PubMed     Abstract available


  54. ZHU X, Patel EU, Berry SA, Grabowski MK, et al
    Brief Report: Trends in Hospital Readmissions Among Adults With and Without HIV in the United States, 2010-2020.
    J Acquir Immune Defic Syndr. 2025;98:334-339.
    PubMed     Abstract available


    March 2025
  55. BUTTS SA, Johnson AL, Doblecki-Lewis S
    PrEP Beyond the Clinic: Evaluation of a Home-Based PrEP Follow-Up System Among a Cohort of Predominantly Black and Latino Men who Have Sex with Men in South Florida.
    J Acquir Immune Defic Syndr. 2025 Mar 28. doi: 10.1097/QAI.0000000000003664.
    PubMed     Abstract available


  56. BANGA J, Nelson BS, Ajibola G, Mohammed T, et al
    Predictive markers for sustained viral suppression on dual bNAbs during ART interruption in children.
    J Acquir Immune Defic Syndr. 2025 Mar 26. doi: 10.1097/QAI.0000000000003663.
    PubMed     Abstract available


  57. KIPTINNESS C, Mugo N, Mugwanya KK, Ngure K, et al
    THE EFFECT OF PARTNER DELIVERY OF HIV SELF-TEST KITS ON HIV TESTING AND LINKAGE TO CARE IN PUBLIC CLINICS IN KENYA.
    J Acquir Immune Defic Syndr. 2025 Mar 26. doi: 10.1097/QAI.0000000000003662.
    PubMed     Abstract available


  58. GUTIERREZ JI JR, Montgomery ET, Dilworth SE, McNulty MC, et al
    Identifying preferred program delivery attributes for long-acting injectable cabotegravir-rilpvirine in three U.S. HIV clinics: A discrete choice experiment.
    J Acquir Immune Defic Syndr. 2025 Mar 13. doi: 10.1097/QAI.0000000000003661.
    PubMed     Abstract available


  59. NJUGUNA I, Moraa H, Mbwayo A, Nyapara F, et al
    "You are the tutor, you are the counselor, you are the school nurse, you are everything": Secondary school staff experience with youth living with HIV.
    J Acquir Immune Defic Syndr. 2025 Mar 11. doi: 10.1097/QAI.0000000000003659.
    PubMed     Abstract available


  60. CHAILLON A, Gaitan NC, Taylor LE, Wu K, et al
    Predictors of Acute HCV Incidence in People with HIV: Insights from a Long-term Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Mar 6. doi: 10.1097/QAI.0000000000003660.
    PubMed     Abstract available


  61. PHILPOTT DC, Curran KG, Russell OO, McClung RP, et al
    HIV Clusters Reported by State and Local Health Departments in the United States, 2020-2022.
    J Acquir Immune Defic Syndr. 2025 Mar 6. doi: 10.1097/QAI.0000000000003658.
    PubMed     Abstract available


  62. DASGUPTA S, Tie Y, Buchacz K, Koenig LJ, et al
    A novel method for assessing poor quality of life among people with HIV.
    J Acquir Immune Defic Syndr. 2025 Mar 5. doi: 10.1097/QAI.0000000000003644.
    PubMed     Abstract available


  63. ZHAO Y, Holtman M, Mudaly V, van Zyl G, et al
    Resistance to Dolutegravir in Treatment-experienced Patients in South Africa: A Retrospective Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Mar 3. doi: 10.1097/QAI.0000000000003657.
    PubMed     Abstract available


  64. KISTAN G, Sebitloane M, Lombard C, Godlwana Z, et al
    Tenofovir Disoproxil Fumarate/Emtricitabine Prophylaxis Has No Effect on Bone Mineral Density and Bone Mineral Content in African Breastfeeding Women Receiving Pre-Exposure Prophylaxis for HIV.
    J Acquir Immune Defic Syndr. 2025;98:265-273.
    PubMed     Abstract available


  65. SMITH MK, Luo D, Meng S, Fei Y, et al
    An Incognito Standardized Patient Approach for Measuring and Reducing Intersectional Healthcare Stigma: A Pilot Cluster Randomized Control Trial.
    J Acquir Immune Defic Syndr. 2025;98:224-233.
    PubMed     Abstract available


  66. VERA M, Sila J, Richardson BA, Otieno F, et al
    Brief Report: Effect of Improved Provider Communication and Adherence to Guidelines on PrEP Initiation in Kisumu Kenya.
    J Acquir Immune Defic Syndr. 2025;98:252-256.
    PubMed     Abstract available


    February 2025
  67. MBENGERANWA T, Ziemba L, Brummel SS, Johnston B, et al
    Bone mineral content, growth, and renal health of infants with perinatal exposure to maternal dolutegravir vs efavirenz and tenofovir disoproxil fumarate vs tenofovir alafenamide: the randomized IMPAACT 2010 (VESTED) trial.
    J Acquir Immune Defic Syndr. 2025 Feb 26. doi: 10.1097/QAI.0000000000003656.
    PubMed     Abstract available


  68. SCONZA R, Fernandes G, Bailey H, Peters H, et al
    Outcomes following prenatal exposure to raltegravir-containing antiretroviral therapy: a multi-cohort European study.
    J Acquir Immune Defic Syndr. 2025 Feb 25. doi: 10.1097/QAI.0000000000003645.
    PubMed     Abstract available


  69. PUTHANAKIT T, Aurpibul L, Lopez M, Wang M, et al
    Efficacy and Safety of the Two-Drug Regimen Dolutegravir/Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-label, Phase 3b Trial.
    J Acquir Immune Defic Syndr. 2025 Feb 24. doi: 10.1097/QAI.0000000000003655.
    PubMed     Abstract available


  70. VINOGRADOV V, Lee YG, Zhakupova G, Mergenova G, et al
    Social Impacts of Multi-City HIV Research Participation Among Sexual and Gender Expansive Individuals in Kazakhstan.
    J Acquir Immune Defic Syndr. 2025 Feb 24. doi: 10.1097/QAI.0000000000003654.
    PubMed     Abstract available


  71. GRAVETT RM, Long DM, Biello KB, Mayer KH, et al
    Preferences for monthly oral PrEP over other PrEP modalities among a national sample of gay, bisexual, and other men who have sex with men in the United States.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003651.
    PubMed     Abstract available


  72. YOUNG J, Wang S, Sacks-Davis R, Stewart A, et al
    Liver fibrosis regression in people living with HIV after successful treatment for hepatitis C.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003646.
    PubMed     Abstract available


  73. LANG R, Coburn SB, Gill MJ, Grossman J, et al
    The Association of Anemia on Non-AIDS Defining Cancer and Subsequent Survival among People with HIV following Antiretroviral Initiation.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003647.
    PubMed     Abstract available


  74. GATHE JC, Dejesus E, Ramgopal MN, Rolle CP, et al
    Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003648.
    PubMed     Abstract available


  75. SHILABYE PS, Scheuermaier K, Vos-Seda AG, Barth RE, et al
    THE ASSOCIATION BETWEEN HIV-RELATED STIGMA, ART ADHERENCE AND CARDIOVASCULAR DISEASE RISK IN PEOPLE LIVING WITH HIV.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003653.
    PubMed     Abstract available


  76. RAMAKRISHNAN A, Goldstein M, Shetty S, Badell M, et al
    Improving Perinatal HIV Care during the COVID-19 Pandemic: Implementing a Mobile Integrated Health Program to Close the Gap.
    J Acquir Immune Defic Syndr. 2025 Feb 13. doi: 10.1097/QAI.0000000000003643.
    PubMed     Abstract available


  77. MOCANU V, Brooks HM, Namasopo S, Opoka RO, et al
    The lived experiences of Ugandan community health workers engaged in prevention of vertical transmission of HIV and a capacity-building intervention.
    J Acquir Immune Defic Syndr. 2025 Feb 13. doi: 10.1097/QAI.0000000000003649.
    PubMed     Abstract available


  78. KOTA KK, Mansergh G, Carnes N, Gelaude D, et al
    Behavioral Readiness for Daily Oral PrEP in a Diverse Sample of Gay, Bisexual, and Other Men who have Sex with Men Who Have Not Been Offered PrEP by a Provider.
    J Acquir Immune Defic Syndr. 2025 Feb 13. doi: 10.1097/QAI.0000000000003650.
    PubMed     Abstract available


  79. ZHENG A, Fox MP, Greener R, Kileel EM, et al
    Initiation of Dolutegravir vs Efavirenz on Viral Suppression and Retention at 6-months: A Regression Discontinuity Design.
    J Acquir Immune Defic Syndr. 2025 Feb 6. doi: 10.1097/QAI.0000000000003642.
    PubMed     Abstract available


  80. SPINELLI MA, Christopoulos KA
    Reply.
    J Acquir Immune Defic Syndr. 2025;98:e12.
    PubMed    


  81. DOMINGUEZ-DOMINGUEZ L, Hamzah L, Fox J, Vincent RP, et al
    Brief Report: Cystatin C Provides Substantially Higher Glomerular Filtration Rate Estimates Than Creatinine in a Subset of Black People With HIV on Current Antiretroviral Regimens.
    J Acquir Immune Defic Syndr. 2025;98:171-175.
    PubMed     Abstract available


  82. TASSIOPOULOS K, John B, Khadraoui A, Salomon L, et al
    Brief Report: Transition Preparation and Post-Transition Evaluation Practices at Adult Clinics That Care for Young Adults With Perinatally Acquired HIV in Massachusetts, United States.
    J Acquir Immune Defic Syndr. 2025;98:103-107.
    PubMed     Abstract available


  83. MAYA S, Sheira LA, Frongillo EA, Pala AN, et al
    Brief Report: Internalized Poverty-Related Stigma and Interpersonal Violence Among Women Living With HIV in the United States.
    J Acquir Immune Defic Syndr. 2025;98:99-102.
    PubMed     Abstract available


    January 2025
  84. MURPHY E, Hoffman S, Ssempijja V, Nalugoda F, et al
    HIV Pre-Exposure Prophylaxis (PrEP) awareness and use among Rakai Community Cohort Study youth aged 15-24.
    J Acquir Immune Defic Syndr. 2025 Jan 31. doi: 10.1097/QAI.0000000000003640.
    PubMed     Abstract available


  85. MARWA MM, Larsen A, Abuna F, Dettinger J, et al
    HIV risk perception and PrEP uptake among pregnant women offered PrEP during antenatal care in Kenya.
    J Acquir Immune Defic Syndr. 2025 Jan 31. doi: 10.1097/QAI.0000000000003641.
    PubMed     Abstract available


  86. MIMIAGA MJ, Kuhns LM, Biello KB, Tian J, et al
    Positive STEPS: Enhancing Medication Adherence and Achieving Viral Load Suppression in Youth Living with HIV in the United States - Results from a Stepped-Care Randomized Controlled Efficacy Trial.
    J Acquir Immune Defic Syndr. 2025 Jan 30. doi: 10.1097/QAI.0000000000003639.
    PubMed     Abstract available


  87. DINIZ CP, Abdul-Massih S, Bagia C, Giguere R, et al
    Rectal Douche as HIV Pre-Exposure Prophylaxis for Receptive Anal Intercourse: An End User Tenofovir Powder Sachet Preparation Feasibility Study (DREAM-04).
    J Acquir Immune Defic Syndr. 2025 Jan 23. doi: 10.1097/QAI.0000000000003608.
    PubMed     Abstract available


  88. BAZAZI AR, Thomas M, Vittinghoff E, Walkup J, et al
    Schizophrenia and retention in HIV care among adults insured through Medicaid in the United States: a population-based retrospective cohort study.
    J Acquir Immune Defic Syndr. 2025 Jan 23. doi: 10.1097/QAI.0000000000003606.
    PubMed     Abstract available


  89. BAXTER A, Gopalappa C, Islam MH, Viguerie A, et al
    Updates to HIV transmission rate estimates along the HIV care continuum in the United States, 2019.
    J Acquir Immune Defic Syndr. 2025 Jan 23. doi: 10.1097/QAI.0000000000003623.
    PubMed     Abstract available


  90. FISK-HOFFMAN RJ, Liu Y, Somboonwit C, Widmeyer M, et al
    What Matters Most for Long-Acting Antiretroviral Therapy? A Best-Worst Scaling Discrete Choice Experiment.
    J Acquir Immune Defic Syndr. 2025 Jan 21. doi: 10.1097/QAI.0000000000003609.
    PubMed     Abstract available


  91. YU B, Jike C, Lan X, Wang J, et al
    Effect of fertility desire-based service on HIV seroconversion among serodiscordant partners: A 12-year retrospective cohort study.
    J Acquir Immune Defic Syndr. 2025 Jan 21. doi: 10.1097/QAI.0000000000003607.
    PubMed     Abstract available


  92. CALZA L, Colangeli V, Giglia M, Rigamonti C, et al
    EFFICACY AND SAFETY OF DOLUTEGRAVIR/LAMIVUDINE IN ANTIRETROVIRAL THERAPY-NAIVE PEOPLE LIVING WITH HIV-1 AND WITH HIGH-LEVEL VIREMIA.
    J Acquir Immune Defic Syndr. 2025 Jan 14. doi: 10.1097/QAI.0000000000003600.
    PubMed     Abstract available


  93. SONG W, Mulatu MS, Crepaz N, Wang G, et al
    Association Between County-Level Social Vulnerability and CDC-funded HIV Testing Program Outcomes in the United States, 2020-2022.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003603.
    PubMed     Abstract available


  94. CARBONE A, Vaccher E, Gloghini A, Pria AD, et al
    Management of KSHV/HHV8 positive Multicentric Castleman Disease concurrent with other KSHV/HHV8 positive disorders. An emergent challenge in PLWH.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003604.
    PubMed    


  95. MARCUS R, Dasgupta S, Taussig J, Tie Y, et al
    Social Determinants of Health and Unmet Needs for Services among Young Adults with HIV: Medical Monitoring Project, 2018-2021.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003605.
    PubMed     Abstract available


  96. CHAN PA, Goedel WC, Li Y, Mena L, et al
    Impact of Social Determinants of Health on Pre-exposure Prophylaxis Care for HIV Prevention.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003601.
    PubMed     Abstract available


  97. JONES J, Siegler AJ, Glick JL, Lucas I, et al
    Potential gains in PrEP coverage and effect on racial disparities following introduction of on-demand and long-acting injectable PrEP: Preferences of men who have sex with men in the United States, 2021-2022.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003602.
    PubMed     Abstract available


  98. TESORIERO JM, Boos EM, Adamashvili N, Massaroni R, et al
    Assessing Gaps in Integrated HIV and STI Testing Among New York State-Funded Providers by Pre-Exposure Prophylaxis Status: Implications for Status-Neutral Programming.
    J Acquir Immune Defic Syndr. 2025 Jan 6. doi: 10.1097/QAI.0000000000003598.
    PubMed     Abstract available


  99. HAAS AD, Kusejko K, Cavassini M, Gunthard H, et al
    Late re-engagement into HIV care among adults in the Swiss HIV Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Jan 3. doi: 10.1097/QAI.0000000000003597.
    PubMed     Abstract available


  100. MOYLE G, Meng F, Wan H, Sklar P, et al
    Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials.
    J Acquir Immune Defic Syndr. 2025 Jan 3. doi: 10.1097/QAI.0000000000003599.
    PubMed     Abstract available


  101. HORTON RH, Mcintosh A, Ostinelli EG, Harriss E, et al
    Neuropsychiatric Outcomes in Children and Adolescents with Perinatally Acquired HIV: A Systematic Review and Meta Analysis.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003595.
    PubMed     Abstract available


  102. SERUNJOGI R, Mumpe-Mwanja D, Williamson DM, Valencia D, et al
    Risk of adverse birth outcomes and birth defects among women living with HIV on antiretroviral therapy and HIV-negative women in Uganda, 2015-2021.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003596.
    PubMed     Abstract available


  103. L T, F M, D V, S B, et al
    Adherence and forgiveness of two modern ART regimens: lamivudine/dolutegravir and emtricitabine/tenofovir alafenamide/rilpivirine.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003594.
    PubMed     Abstract available


  104. DANG T, Anderson J, Powell AM
    Factors Associated with Retention in HIV Care within 12 months Postpartum: A Retrospective Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003593.
    PubMed     Abstract available


  105. ANDERSON KM, Sheth AN, Sales JM
    Exploring PrEP Motivation as a Modifiable Target for HIV Prevention Uptake for Cisgender Women in Atlanta, Georgia.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003587.
    PubMed     Abstract available


  106. ANDERSON K, Rabie H, Eley BS, Frigati L, et al
    High incidence of tuberculosis in young children living with HIV in the Western Cape, South Africa.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003591.
    PubMed     Abstract available


  107. JALIL CM, Teixeira SLM, Coutinho C, Nazer SC, et al
    Impact of COVID-19 Pandemic on HIV Testing, Recent Infections, and Annualized Incidence Among Cisgender Men Who Have Sex With Men and Transgender Women in Brazil.
    J Acquir Immune Defic Syndr. 2025;98:12-19.
    PubMed     Abstract available


  108. MURPHY M, Rogers B, Galipeau D, Toma E, et al
    HIV Pre-exposure Prophylaxis Use Among Men Experiencing Incarceration in the United States: A Prospective Cohort Study.
    J Acquir Immune Defic Syndr. 2025;98:41-48.
    PubMed     Abstract available


  109. ABRAHAM BK, Vogler M, Talati A, Suresh P, et al
    Pregnancy Outcomes and All-Cause Mortality After Pregnancy Among US-Born Women With Perinatally Acquired HIV.
    J Acquir Immune Defic Syndr. 2025;98:20-28.
    PubMed     Abstract available


  110. HUANG YA, Lowy E, Zhu W, Yu L, et al
    Brief Report: Preexposure Prophylaxis Use Among U.S. Veterans Using Veterans Health Administration Services, 2014 horizontal line 2022.
    J Acquir Immune Defic Syndr. 2025;98:8-11.
    PubMed     Abstract available


    December 2024
  111. GLASS DJ, Kinge M, Njuguna I, McGrath CJ, et al
    Poorer longitudinal growth among HIV exposed compared to unexposed infants in Kenya.
    J Acquir Immune Defic Syndr. 2024 Dec 27. doi: 10.1097/QAI.0000000000003592.
    PubMed     Abstract available


  112. FISHER MC, Hanna DB, Fazzari M, Felsen UR, et al
    Preadmission VACS Index as a Predictor of Hospital Acute Kidney Injury in People with HIV.
    J Acquir Immune Defic Syndr. 2024 Dec 27. doi: 10.1097/QAI.0000000000003589.
    PubMed     Abstract available


  113. ROSENBERG NE, Graybill LA, Mtande T, McGrath N, et al
    The impact of a couple-based intervention on one-year viral suppression among pregnant women living with HIV and their male partners in Malawi: A randomized controlled trial.
    J Acquir Immune Defic Syndr. 2024 Dec 23. doi: 10.1097/QAI.0000000000003583.
    PubMed     Abstract available


  114. BEESHAM I, Jaggernath M, Kriel Y, Hao J, et al
    Longitudinal changes in tenofovir and tenofovir-diphosphate concentrations among pregnant women using oral PrEP for HIV prevention: Findings from Durban, South Africa.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003586.
    PubMed     Abstract available


  115. GUTREUTER S, Denhard L, Logan JE, Blanton J, et al
    Model-Based Prioritization of Adolescent Girls and Young Women for HIV Prevention Services Based on Data from 13 Sub-Saharan African Countries.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003588.
    PubMed     Abstract available


  116. HUANG YA, Chang MH, Zhu W, Hoover KW, et al
    Uptake of HIV Preexposure Prophylaxis Among Medicare Beneficiaries - United States, 2014-2021.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003590.
    PubMed     Abstract available


  117. CHAWKI S, Hamet G, Brun A, Lourenco N, et al
    Pancreatic cancer in people with HIV: a case-control study.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003585.
    PubMed     Abstract available


  118. TAN DHS, Antinori A, Eu B, Galindo Puerto MJ, et al
    Weight and metabolic changes with long-acting cabotegravir and rilpivirine or bictegravir/emtricitabine/tenofovir alafenamide.
    J Acquir Immune Defic Syndr. 2024 Dec 16. doi: 10.1097/QAI.0000000000003584.
    PubMed     Abstract available



  119. Early Efficacy and Safety of the Third Dose Inactivated COVID-19 Vaccine Among People Living With HIV: Erratum.
    J Acquir Immune Defic Syndr. 2024;97:e30.
    PubMed    


  120. THORP M, Phiri S, Phiri K, Robson I, et al
    Brief Report: Stated Preferences for Long-Acting Injectable ART Among Mobile Men Living With HIV in Malawi: A Qualitative Study.
    J Acquir Immune Defic Syndr. 2024;97:e25-e29.
    PubMed     Abstract available


  121. HASTIE E, Srivatsa MS, Gianella S, Cottrell M, et al
    Brief Report: Genital Microbiome, Inflammation, and Tenofovir Levels in Transgender Men and Cisgender Women Taking Oral PrEP.
    J Acquir Immune Defic Syndr. 2024;97:477-481.
    PubMed     Abstract available


  122. PAINE EA, Appenroth M, Scheim A, Goldrich M, et al
    Brief Report:Availability of and Interest in Gender-Affirming Care, PrEP, and HIV Prevention Services in a Global Sample of Transmasculine Persons.
    J Acquir Immune Defic Syndr. 2024;97:471-476.
    PubMed     Abstract available


  123. KRENISKE P, Nalugoda F, Chen I, Parate N, et al
    Brief Report: Antiretroviral Treatment Use Over Time Among Adolescents and Young Adults in the Rakai Community Cohort Study, 2011-2020.
    J Acquir Immune Defic Syndr. 2024;97:433-438.
    PubMed     Abstract available


  124. GOLUB SA, Wolfer C, Chastain CA
    INCREASING THE ACCESSIBILITY AND RELEVANCE OF IMPLEMENTATION SCIENCE FOR FRONT-LINE IMPLEMENTERS.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003580.
    PubMed     Abstract available


  125. VOLPI C, Adebiyi R, Chama J, Ononaku U, et al
    Impact of Age of Sexual Debut on HIV Care Engagement among Sexual and Gender Minorities in Nigeria.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003574.
    PubMed     Abstract available


  126. WU L, Ssebuliba T, Muwonge TR, Bambia F, et al
    ALIGNMENT OF PREP USE WITH POTENTIAL HIV EXPOSURE IN YOUNG WOMEN AND MEN IN UGANDA.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003573.
    PubMed     Abstract available


  127. KUGLEN B, Clay C, Boothroyd D, Bennett CL, et al
    Estimated Impact of HIV Testing on Length of Stay at Visits to United States Emergency Departments, 2018-2021.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003575.
    PubMed    


  128. GOLUB SA, Wolfer C, Beacham A, Lane BV, et al
    DEVELOPING A PRACTICE-DRIVEN TAXONOMY OF IMPLEMENTATION STRATEGIES FOR HIV PREVENTION.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003581.
    PubMed     Abstract available


  129. MATTIE H, Goyal R, De Gruttola V, Onnela JP, et al
    A review of network models for HIV spread.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003578.
    PubMed     Abstract available


  130. WANG RJ, Kunisaki KM, Morris A, Drummond MB, et al
    The implications of removing race from interpretation of pulmonary function among persons with or without HIV.
    J Acquir Immune Defic Syndr. 2024 Dec 3. doi: 10.1097/QAI.0000000000003579.
    PubMed     Abstract available


  131. MUNROE S, Schackman BR, Madkins K, Saber R, et al
    Economic Evaluation of delivering an evidence-based online HIV prevention program to MSM via direct-to-consumer marketing versus community-based organization recruitment.
    J Acquir Immune Defic Syndr. 2024 Dec 2. doi: 10.1097/QAI.0000000000003572.
    PubMed     Abstract available


  132. HO K, Hoesley C, Anderson PL, Fernandez-Romero JA, et al
    Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037).
    J Acquir Immune Defic Syndr. 2024;97:379-386.
    PubMed     Abstract available


  133. CARNEIRO PB, Radix AE, Golub S, Grosskopf N, et al
    PrEP Use in a US National Sample of Trans Men and Other Transmasculine People Who Have Sex With Men: A Longitudinal Analysis.
    J Acquir Immune Defic Syndr. 2024;97:357-363.
    PubMed     Abstract available


    November 2024
  134. KISTAN G, Sebitloane M, Lombard C, Godlwana Z, et al
    Tenofovir Disoproxil Fumarate/Emtricitabine Prophylaxis Has No Effect on Bone Mineral Density and Bone Mineral Content in African Breastfeeding Women Receiving Pre-Exposure Prophylaxis for HIV.
    J Acquir Immune Defic Syndr. 2024 Nov 27. doi: 10.1097/QAI.0000000000003563.
    PubMed     Abstract available


  135. DUNN DT, McCabe L, Ward D, Phillips AN, et al
    Assessing whether providing regular, free HIV self-testing kits reduces the time to HIV diagnosis: an internet-based, randomised controlled trial in men who have sex with men.
    J Acquir Immune Defic Syndr. 2024 Nov 22. doi: 10.1097/QAI.0000000000003564.
    PubMed     Abstract available


  136. EGER WH, Shaw LC, Biello KB, Lopez C, et al
    HIV pre-exposure prophylaxis prescription initiation and maintenance among homeless-experienced people who use drugs.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003568.
    PubMed     Abstract available


  137. SMITH MK, Luo D, Meng S, Fei Y, et al
    An Incognito Standardized Patient Approach for Measuring and Reducing Intersectional Healthcare Stigma: A Pilot Cluster Randomized Control Trial.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003565.
    PubMed     Abstract available


  138. DEVANATHAN AS, Poliseno AJ, White NR, Schauer AP, et al
    A Cross-Biomeasure Study to Optimize Antiretroviral Adherence Estimation.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003570.
    PubMed     Abstract available


  139. POWIS KM, Pinilla M, McMorrow F, Stek A, et al
    Pharmacokinetics and safety of bictegravir in pregnant and postpartum persons with HIV and their infants.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003571.
    PubMed     Abstract available


  140. MANAVALAN P, Gadkowski LB, Sachdeva A, Guha S, et al
    Acceptability of multi-level sexual health interventions and sexually transmitted infection screening and testing among persons with HIV across three clinical sites in Florida.
    J Acquir Immune Defic Syndr. 2024 Nov 20. doi: 10.1097/QAI.0000000000003569.
    PubMed     Abstract available


  141. YANG X, Cai R, Ma Y, Zhang HH, et al
    Using machine learning techniques to predict viral suppression among people with HIV.
    J Acquir Immune Defic Syndr. 2024 Nov 19. doi: 10.1097/QAI.0000000000003561.
    PubMed     Abstract available


  142. DOS SANTOS FC, Garofalo R, Kuhns L, Scherr T, et al
    Evaluating the Effectiveness of a Mobile Health Intervention on Enhancing HIV Knowledge in Sexual and Gender Minority Men.
    J Acquir Immune Defic Syndr. 2024 Nov 19. doi: 10.1097/QAI.0000000000003562.
    PubMed     Abstract available


  143. PEREZ-BRUMER A, Apedaile D, Leon-Morris F, Huerta L, et al
    Migration is associated with increased HIV vulnerability among young transgender women in Lima, Peru.
    J Acquir Immune Defic Syndr. 2024 Nov 15. doi: 10.1097/QAI.0000000000003560.
    PubMed     Abstract available


  144. ALESSIA S, Sara D, Laura G, Camilla M, et al
    Non-liver malignancies as main cause of mortality after HCV eradication among people living with HIV.
    J Acquir Immune Defic Syndr. 2024 Nov 7. doi: 10.1097/QAI.0000000000003559.
    PubMed     Abstract available


  145. HILL L, Yin J, Patel N, Abulhosn K, et al
    Predictors of Injection Visit Adherence in Those Receiving Injectable Cabotegravir/Rilpivirine.
    J Acquir Immune Defic Syndr. 2024 Nov 5. doi: 10.1097/QAI.0000000000003556.
    PubMed     Abstract available


  146. HUMPHREY J, Kipchumba B, Alera M, Sang E, et al
    Outcomes After Loss to Follow-Up for Pregnant and Postpartum Women Living With HIV and Their Children in Kenya: A Prospective Cohort Study.
    J Acquir Immune Defic Syndr. 2024;97:242-252.
    PubMed     Abstract available


  147. BAILEY JR, Fonseca E, Borsa A, Hawryluk E, et al
    Three Novel Patient-Reported Outcome Measures to Assess the Patient Experience With Daily and Weekly HIV Oral Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;97:286-295.
    PubMed     Abstract available


  148. AULD SC, Harrington KRV, Nguyen MLT, Colasanti JA, et al
    Brief Report: Alternative Pulmonary Function Measures of Emphysema in People With HIV.
    J Acquir Immune Defic Syndr. 2024;97:282-285.
    PubMed     Abstract available


  149. COMINS CA, Mcingana M, Genberg B, Mulumba N, et al
    Contextual Factors Influencing Implementation of HIV Treatment Support Strategies for Female Sex Workers Living With HIV in South Africa: A Qualitative Analysis Using the Consolidated Framework for Implementation Research.
    J Acquir Immune Defic Syndr. 2024;97:273-281.
    PubMed     Abstract available


  150. LEE CL, Low A, Kreniske P, Mugurungi O, et al
    HIV Outcomes Among Women Living With HIV Who Experienced Early Sexual Violence Across Four Sub-Saharan African Countries.
    J Acquir Immune Defic Syndr. 2024;97:253-260.
    PubMed     Abstract available


  151. CHANDRAN A, Feng X, Coburn SB, Kasaie P, et al
    The Contribution of Socioeconomic Factors to HIV RNA Suppression in Persons With HIV Engaged in Care in the NA-ACCORD.
    J Acquir Immune Defic Syndr. 2024;97:232-241.
    PubMed     Abstract available


  152. ZHABOKRITSKY A, Klein M, Harris M, Loutfy M, et al
    Prevalence and Correlates of Frailty Among Older Adults Living With HIV in the CHANGE HIV Cohort.
    J Acquir Immune Defic Syndr. 2024;97:226-231.
    PubMed     Abstract available


  153. CHAGOMERANA MB, Moser CB, Kang M, Umbleja T, et al
    Mortality and Associated Risk Factors Among People Living With HIV With Kaposi Sarcoma: A5263/AMC066 and A5264/AMC067.
    J Acquir Immune Defic Syndr. 2024;97:216-225.
    PubMed     Abstract available


  154. WULANDARI LPL, Negara SNS, Mashuri YA, Wahyuningtias SD, et al
    A Systematic Review and Meta-analysis of the Impact of the COVID-19 Pandemic on Access to HIV Pre-exposure Prophylaxis: Lessons for Future Public Health Crises.
    J Acquir Immune Defic Syndr. 2024;97:208-215.
    PubMed     Abstract available


  155. HAZIM CE, Coutinho J, Crocker J, Asbjornsdottir K, et al
    Posttrial Experiences in Sustainment of a Scaled Model of the Systems Analysis and Improvement Approach (SAIA-SCALE) in the Absence of External Funding in Manica Province, Mozambique.
    J Acquir Immune Defic Syndr. 2024;97:203-207.
    PubMed     Abstract available


    October 2024
  156. YOUNG R, Ssekasanvu J, Kagaayi J, Ssekubugu R, et al
    HIV and viremia prevalence in non-migrating members of migrant households in southern Uganda: A cross-sectional population-based study.
    J Acquir Immune Defic Syndr. 2024 Oct 31. doi: 10.1097/QAI.0000000000003553.
    PubMed     Abstract available


  157. DAUNGSUPAWONG H, Wiwanitkit V
    Comment on "Prevalence and Correlates of SARS-CoV-2 Vaccine Uptake and Hesitancy Among People With HIV Across the United States".
    J Acquir Immune Defic Syndr. 2024 Oct 30. doi: 10.1097/QAI.0000000000003554.
    PubMed    


  158. TIAMIYU AB, Hu F, Kokogho A, Charurat ME, et al
    Discussion of HIV and Other Sexually Transmitted Infections with Sex Partners of Nigerian Men who have Sex with Men and Transgender Women: Implications for Interventions to Promote Safer Sex Practices.
    J Acquir Immune Defic Syndr. 2024 Oct 24. doi: 10.1097/QAI.0000000000003552.
    PubMed     Abstract available


  159. BERNARD C, Font H, Zotova N, Wools-Kaloustian K, et al
    Accuracy of alternative PHQ-9 scoring algorithms to screen for depression in people living with HIV in Sub-Saharan Africa.
    J Acquir Immune Defic Syndr. 2024 Oct 24. doi: 10.1097/QAI.0000000000003551.
    PubMed     Abstract available


  160. KRIS H, Anders B, Daniela K VS, Kees B, et al
    Hepatitis C treatment and behavioural risk among men who have sex with men with HIV: comparing interferon and direct-acting antiviral eras.
    J Acquir Immune Defic Syndr. 2024 Oct 24. doi: 10.1097/QAI.0000000000003550.
    PubMed     Abstract available


  161. TAIWO BO, Kuhns LM, Agbaji O, David A, et al
    A Stepped-Wedge, Cluster-Randomized, Multisite Study of Text Messaging Plus Peer Navigation to Improve Adherence and Viral Suppression Among Youth on Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024 Oct 18. doi: 10.1097/QAI.0000000000003549.
    PubMed     Abstract available


  162. MAGAGNOLI J, Cummings TH, Wyatt MD, Shtutman M, et al
    Schizophrenia, Off-Label Antipsychotics, and Dementia Risk in People with HIV.
    J Acquir Immune Defic Syndr. 2024 Oct 17. doi: 10.1097/QAI.0000000000003545.
    PubMed     Abstract available


  163. ROGERS B, Ramsey S, Ames E, Gomes N, et al
    Addressing barriers to implementing and scaling PrEP in carceral settings: Applying insights from implementation science.
    J Acquir Immune Defic Syndr. 2024 Oct 10. doi: 10.1097/QAI.0000000000003547.
    PubMed     Abstract available


  164. RACCAGNI AR, Passini F, Diotallevi S, Lolatto R, et al
    Gaps in HIV Pre-exposure Prophylaxis Acceptance: Findings from an Outpatient HIV Testing Service in Italy.
    J Acquir Immune Defic Syndr. 2024 Oct 8. doi: 10.1097/QAI.0000000000003544.
    PubMed     Abstract available


  165. FINN B, Vanessa M, Xochitl LM, Emily P, et al
    Addressing methamphetamine use is essential to stopping HIV transmission.
    J Acquir Immune Defic Syndr. 2024 Oct 7. doi: 10.1097/QAI.0000000000003542.
    PubMed    


  166. KOTA KK, Eppink S, Gant Z, Chesson H, et al
    Racial and Ethnic Disparities in HIV Diagnosis Rates by Social Determinants of Health at the Census Tract Level among Adults in the United States and Puerto Rico, 2021.
    J Acquir Immune Defic Syndr. 2024 Oct 4. doi: 10.1097/QAI.0000000000003541.
    PubMed     Abstract available


  167. BURNETT J, Olansky E, Baugher AR, Lee K, et al
    Intersecting structural and psychosocial conditions: investigating injection drug use and HIV among transgender women.
    J Acquir Immune Defic Syndr. 2024 Oct 4. doi: 10.1097/QAI.0000000000003543.
    PubMed     Abstract available


  168. COLER B, Smith GH, Arora AK, Wells A, et al
    Quality of Life in People with HIV at the End of Life: Preliminary Results from the Last Gift Observational Cohort Study.
    J Acquir Immune Defic Syndr. 2024 Oct 3. doi: 10.1097/QAI.0000000000003536.
    PubMed     Abstract available



  169. Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
    J Acquir Immune Defic Syndr. 2024;97:202.
    PubMed    


  170. ORR JE, Velazquez J, Schmickl CN, Bosompra NO, et al
    Sleep, Sleep Apnea, and Fatigue in People Living With HIV.
    J Acquir Immune Defic Syndr. 2024;97:192-201.
    PubMed     Abstract available


  171. LAZZARO A, Vai D, Barco A, Stroffolini G, et al
    Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2024;97:180-191.
    PubMed     Abstract available


  172. MASHETO G, Brummel SS, Ziemba L, Shepherd J, et al
    Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial.
    J Acquir Immune Defic Syndr. 2024;97:172-179.
    PubMed     Abstract available


  173. DEBROY P, Barrett BW, Erlandson KM, Budoff M, et al
    Relationships Between Hepatic Steatosis and Frailty Differ by HIV Serostatus.
    J Acquir Immune Defic Syndr. 2024;97:165-171.
    PubMed     Abstract available


  174. AOUIZERAT BE, Garcia JN, Domingues CV, Xu K, et al
    Frequent Cocaine Use is Associated With Larger HIV Latent Reservoir Size.
    J Acquir Immune Defic Syndr. 2024;97:156-164.
    PubMed     Abstract available


  175. BELTRAN RM, Hunter LA, Packel LJ, De Martini L, et al
    A Mixed Methods Evaluation of Pharmacists' Readiness to Provide Long-Acting Injectable HIV Pre-exposure Prophylaxis in California.
    J Acquir Immune Defic Syndr. 2024;97:142-149.
    PubMed     Abstract available


  176. MACGOWAN RJ, Chavez PR, Dana R, Hannah M, et al
    Efficacy of Internet Recruitment and HIV Self-Testing for Diagnosing HIV Infections Among Black and Hispanic/Latino MSM and Transgender Women in 11 US States, 2020-2021.
    J Acquir Immune Defic Syndr. 2024;97:133-141.
    PubMed     Abstract available


  177. MUJUGIRA A, Karungi B, Nakyanzi A, Bagaya M, et al
    Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial.
    J Acquir Immune Defic Syndr. 2024;97:125-132.
    PubMed     Abstract available


  178. MCDONALD SA, Yeung A, Nandwani R, Clutterbuck D, et al
    A Statistical Model for Inference of Recent and Incident HIV Infection Using Surveillance Data on Individuals Newly Diagnosed With HIV Infection in Scotland.
    J Acquir Immune Defic Syndr. 2024;97:117-124.
    PubMed     Abstract available


  179. YANG X, Zhang J, Chen S, Liu Z, et al
    COVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis.
    J Acquir Immune Defic Syndr. 2024;97:107-116.
    PubMed     Abstract available


  180. YIGIT I, Budhwani H, Rainer CB, Claude K, et al
    Associations Between PrEP Stigma, PrEP Confidence, and PrEP Adherence: Conditional Indirect Effects of Anticipated HIV Stigma.
    J Acquir Immune Defic Syndr. 2024;97:99-106.
    PubMed     Abstract available


  181. OKEGBE T, Bishop KM, Rose J, Srivastava M, et al
    Trends in the Uptake of Index Testing among Adolescents in USAID-Supported PEPFAR Programs, October 2017- September 2022.
    J Acquir Immune Defic Syndr. 2024 Oct 1. doi: 10.1097/QAI.0000000000003540.
    PubMed     Abstract available


  182. FAIRLIE L, Brummel S, Ziemba L, Coletti A, et al
    Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV.
    J Acquir Immune Defic Syndr. 2024;97:150-155.
    PubMed     Abstract available


    September 2024
  183. HONG HANH NT, Phuong Tram PT, Thanh Ha HT, Duc BH, et al
    Detection of antiretroviral drug-resistant mutations and HIV-1 subtypes in circulation among men who have sex with men, SEM females and female sex workers: results of Vietnam's HIV Sentinel Surveillance Plus (HSS+) system, 2018 - 2020.
    J Acquir Immune Defic Syndr. 2024 Sep 26. doi: 10.1097/QAI.0000000000003537.
    PubMed     Abstract available


  184. EDELMAN EJ, Dziura J, Deng Y, DePhilippis D, et al
    Integrated stepped alcohol treatment with contingency management for unhealthy alcohol use among people with HIV: A randomized controlled trial.
    J Acquir Immune Defic Syndr. 2024 Sep 25. doi: 10.1097/QAI.0000000000003534.
    PubMed     Abstract available


  185. GUTEMA Y, Lulseged S, Getachew M, Getahun M, et al
    Index-linked Assisted HIV Self-Testing for Children 2-14 Years: Results of a Pilot Evaluation in Ethiopia.
    J Acquir Immune Defic Syndr. 2024 Sep 25. doi: 10.1097/QAI.0000000000003533.
    PubMed     Abstract available


  186. ZINGONI ZM, Okano JT, Ponce J, Dullie L, et al
    Modeling travel-time to HIV treatment in Malawi: identifying rural-urban and wealth inequities.
    J Acquir Immune Defic Syndr. 2024 Sep 24. doi: 10.1097/QAI.0000000000003539.
    PubMed    


  187. JALIL CM, Maia Teixeira SL, Coutinho C, Nazer SC, et al
    Impact of Covid-19 pandemic on HIV testing, recent infections and annualized incidence among cisgender men who have sex with men and transgender women in Brazil.
    J Acquir Immune Defic Syndr. 2024 Sep 18. doi: 10.1097/QAI.0000000000003531.
    PubMed     Abstract available


  188. SELZER L, VanderVeen LA, Parvangada A, Martin R, et al
    Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People with HIV-1 Suppressed by Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024 Sep 18. doi: 10.1097/QAI.0000000000003528.
    PubMed     Abstract available


  189. ANGULIQUE O, Thomas T, Karen M, Monique J, et al
    Motivational Enhancement System for Adherence (MESA) for Adolescents and Young Adults Newly Recommended to Start Antiretroviral Therapy (ART).
    J Acquir Immune Defic Syndr. 2024 Sep 17. doi: 10.1097/QAI.0000000000003530.
    PubMed     Abstract available


  190. CORBETT C, van Rensburg R, Brey N, O'Hagan S, et al
    Timing of ART initiation associated with HIV-associated stroke.
    J Acquir Immune Defic Syndr. 2024 Sep 17. doi: 10.1097/QAI.0000000000003529.
    PubMed    


  191. WEIJSENFELD A, van der Knaap L, Sattoe J, van Staa A, et al
    Health-related quality of life in young adults with perinatal HIV after transfer to adult health care in the Netherlands.
    J Acquir Immune Defic Syndr. 2024 Sep 12. doi: 10.1097/QAI.0000000000003526.
    PubMed     Abstract available


  192. REISNER SL, Humes E, Stevenson M, Cooney EE, et al
    Site-based and Digital Cohort Participation Among Transgender Women in the Eastern and Southern USA: Findings from the LITE Study.
    J Acquir Immune Defic Syndr. 2024 Sep 12. doi: 10.1097/QAI.0000000000003527.
    PubMed     Abstract available


  193. MICHAEL HU, Brouillette MJ, Tamblyn R, Fellows LK, et al
    Disentangling the Effects of Comorbidity and Polypharmacy on Cognitive Function and Physical Frailty in Individuals with HIV.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003523.
    PubMed     Abstract available


  194. BELL GJ, Chen JS, Maierhofer CN, Matoga M, et al
    Updated Risk Score Algorithms for Acute HIV Infection Detection at a Sexually Transmitted Infections Clinic in Lilongwe, Malawi.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003519.
    PubMed     Abstract available


  195. DEJESUS E, Towner WJ Jr, Gathe JC, Cash RB, et al
    Efficacy and safety of two fixed doses of ibalizumab plus optimized background regimen in treatment-experienced HIV-positive individuals.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003524.
    PubMed     Abstract available


  196. EL-HIBRI F, Al-Hindawi A, Singh S, Bower M, et al
    Outcomes of lymphoma patients admitted to the ICU are not influenced by HIV status: a retrospective, observational cohort study.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003522.
    PubMed     Abstract available


  197. BATOHI N, Shalekoff S, Martinson NA, Ebrahim O, et al
    HIV-1 Elite Controllers are Characterised by Elevated Levels of CD69-Expressing Natural Killer Cells.
    J Acquir Immune Defic Syndr. 2024 Sep 2. doi: 10.1097/QAI.0000000000003518.
    PubMed     Abstract available


  198. DA CUNHA GH, Fontenele MSM, Galvao MTG, Dantas MB, et al
    Factors Associated With Symptoms of Anxiety and Depression in People Living With HIV in Northeast Brazil.
    J Acquir Immune Defic Syndr. 2024;97:87-98.
    PubMed     Abstract available


  199. BERNARD I, Ransy DG, Brophy J, Kakkar F, et al
    Lower Neutrophil Count Without Clinical Consequence Among Children of African Ancestry Living With HIV in Canada.
    J Acquir Immune Defic Syndr. 2024;97:78-86.
    PubMed     Abstract available


  200. PENCE BW, Darnell D, Ranna-Stewart M, Psaros C, et al
    Provocative Findings From a Transdiagnostic Counseling Intervention to Improve Psychiatric Comorbidity and HIV Care Engagement Among People With HIV: A Pilot Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2024;97:68-77.
    PubMed     Abstract available


  201. DEROSE KP, Palar K, Then-Paulino A, Han B, et al
    Changes in HIV Internalized and Experienced Stigmas and Social Support After an Urban Gardens and Peer Nutritional Counseling Intervention Among People With HIV and Food Insecurity in the Dominican Republic.
    J Acquir Immune Defic Syndr. 2024;97:55-62.
    PubMed     Abstract available


  202. FULTON J, Novitsky V, Gillani F, Guang A, et al
    Integrating HIV Cluster Analysis in Everyday Public Health Practice: Lessons Learned From a Public Health--Academic Partnership.
    J Acquir Immune Defic Syndr. 2024;97:48-54.
    PubMed     Abstract available


  203. NETHI AK, Karam AG, Alvarez KS, Luque AE, et al
    Using Machine Learning to Identify Patients at Risk of Acquiring HIV in an Urban Health System.
    J Acquir Immune Defic Syndr. 2024;97:40-47.
    PubMed     Abstract available


  204. ROGERS BG, Toma E, Harkness A, Arnold T, et al
    "Why Not Just go on PrEP?": A Study to Inform Implementation of an HIV Prevention Intervention Among Hispanic/Latino Men Who Have Sex With Men in the Northeastern United States.
    J Acquir Immune Defic Syndr. 2024;97:26-39.
    PubMed     Abstract available


  205. SPINELLI MA, Johnson MO, Lisha NE, Jain JP, et al
    Prevalence and Correlates of SARS-CoV-2 Vaccine Uptake and Hesitancy Among People With HIV Across the United States.
    J Acquir Immune Defic Syndr. 2024;97:13-18.
    PubMed     Abstract available


  206. UNTERNAHER J, Koay WLA, Mareuil J, Williams T, et al
    Progress in Eliminating Perinatal HIV Transmission in the Metropolitan DC Area Between 2018-2022.
    J Acquir Immune Defic Syndr. 2024;97:6-12.
    PubMed     Abstract available


  207. YAN CY, Cooley SA, Ances BM
    Veterans Aging Cohort Study Index 2.0 Shows Improved Discrimination of Neurocognitive Impairment and Frailty in People with HIV.
    J Acquir Immune Defic Syndr. 2024;97:63-67.
    PubMed     Abstract available


    August 2024
  208. WALTERS MK, Korenromp EL, Yakusik A, Wanyeki I, et al
    Guidance for triangulating data and estimates of HIV prevalence among pregnant women and coverage of PMTCT using the Spectrum AIDS Impact Module.
    J Acquir Immune Defic Syndr. 2024 Aug 27. doi: 10.1097/QAI.0000000000003514.
    PubMed     Abstract available


  209. REITSEMA M, Wallinga J, van Sighem AI, Bezemer D, et al
    Impact of varying pre-exposure prophylaxis programs on HIV and Neisseria gonorrhoeae transmission among MSM in the Netherlands: a modelling study.
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003511.
    PubMed     Abstract available


  210. JOHN SA, Walsh JL, Doherty RM, Rine SR, et al
    Determinants of potential HIV vaccine uptake among young sexual minoritized men 17-24 years old.
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003517.
    PubMed     Abstract available


  211. MBABAZI P, Chen G, Ritchie CS, Tsai AC, et al
    Prevalence and correlates of frailty among older people with and without HIV in rural Uganda.
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003513.
    PubMed     Abstract available


  212. JIAMSAKUL A, Rupasinghe D, Woolley I, Choi JY, et al
    HIV treatment outcomes after 10 years on ART in the TREAT Asia Observational Database (TAHOD) and Australian HIV Observational Database (AHOD).
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003515.
    PubMed     Abstract available


  213. NALINTYA E, Sekar P, Namakula OL, Tadeo KK, et al
    The diagnostic performance of the Visitect Advanced Disease point-of-care CD4 platform: a pragmatic mixed-methods multisite validation, costing, and qualitative analysis.
    J Acquir Immune Defic Syndr. 2024 Aug 19. doi: 10.1097/QAI.0000000000003505.
    PubMed     Abstract available


  214. MSOSA TC, Swai I, Aarnoutse R, Rinke de Wit TF, et al
    The Effect of Real-Time Medication Monitoring-Based Digital Adherence Tools on Adherence to Antiretroviral Therapy and Viral Suppression in People Living With HIV: A Systematic Literature Review and Meta-Analysis.
    J Acquir Immune Defic Syndr. 2024;96:411-420.
    PubMed     Abstract available


  215. SHORER EF, Dastgheyb RM, French AL, Daubert E, et al
    Tryptophan-Kynurenine Pathway Activation and Cognition in Virally Suppressed Women With HIV.
    J Acquir Immune Defic Syndr. 2024;96:494-500.
    PubMed     Abstract available


  216. MARTIN TCS, Smith LR, Anderson C, Little SJ, et al
    Randomized Controlled Trial of 60 minutes for Health With Rapid Antiretroviral Therapy to Reengage Persons With HIV Who Are Out of Care.
    J Acquir Immune Defic Syndr. 2024;96:486-493.
    PubMed     Abstract available


  217. JONSSON-OLDENBUTTEL C, Ghosn J, van der Valk M, Florence E, et al
    Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
    J Acquir Immune Defic Syndr. 2024;96:472-480.
    PubMed     Abstract available


  218. HOFFMANN CJ, Herce ME, Chimoyi L, Smith HJ, et al
    Reaching for 90:90:90 in Correctional Facilities in South Africa and Zambia: Virtual Cross-Section of Coverage of HIV Testing and Antiretroviral Therapy During Universal Test and Treat Implementation.
    J Acquir Immune Defic Syndr. 2024;96:465-471.
    PubMed     Abstract available


  219. ROY PALADHI U, Katz DA, Otieno G, Hughes JP, et al
    Effectiveness of Using Additional HIV Self-Test Kits as an Incentive to Increase HIV Testing Within Assisted Partner Services.
    J Acquir Immune Defic Syndr. 2024;96:457-464.
    PubMed     Abstract available


  220. NICOLAU IA, Moineddin R, Brooks JD, Antoniou T, et al
    Associations of CD4 Cell Count Measures With Infection-Related and Infection-Unrelated Cancer Risk Among People With HIV.
    J Acquir Immune Defic Syndr. 2024;96:447-456.
    PubMed     Abstract available


  221. HERNANDEZ AL, Hilton JF, Weatherly CS, Berry-Lawhorn JM, et al
    Prevalence of Anal Human Papillomavirus Infection and Anal High-Grade Squamous Intraepithelial Lesions Among Men Who Have Sex With Men 50 Years and Older Living With or Without HIV.
    J Acquir Immune Defic Syndr. 2024;96:439-446.
    PubMed     Abstract available


  222. BARTH SK, Monroe AK, Houston P, Benator D, et al
    COVID-19 Incidence, Risk Factors, Impact, and Related Stigma Among a Cohort of Persons With HIV in Washington, DC.
    J Acquir Immune Defic Syndr. 2024;96:429-438.
    PubMed     Abstract available


  223. SAVINELLI S, McGettrick P, Garcia Leon AA, Tinago W, et al
    Obesity is associated with higher levels of circulating cytokines involved in the development of cardiovascular disease in people living with HIV.
    J Acquir Immune Defic Syndr. 2024 Aug 15. doi: 10.1097/QAI.0000000000003508.
    PubMed     Abstract available


  224. RUSSELL ES, Zhou M, Song Y, Barak N, et al
    Patterns of HIV treatment preferences among people with diverse demographic, social, and behavioral characteristics who are living with HIV in the United States.
    J Acquir Immune Defic Syndr. 2024 Aug 15. doi: 10.1097/QAI.0000000000003509.
    PubMed     Abstract available


  225. ISLAS-MUNOZ B, Chavez-Galan L, Ramon-Luing L, Flores-Gonzalez J, et al
    Comparison of IL-6, IL-10, and TNFalpha levels between PLWHIV with and without Kaposi Sarcoma and healthy controls.
    J Acquir Immune Defic Syndr. 2024 Aug 15. doi: 10.1097/QAI.0000000000003507.
    PubMed     Abstract available


  226. CYKTOR JC, Yeh E, Ribaudo H, Hoeth D, et al
    Brief Report: Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 Infection.
    J Acquir Immune Defic Syndr. 2024;96:481-485.
    PubMed     Abstract available


  227. ROSS JL, Teeraananchai S, Avihingsanon A, Lee MP, et al
    Brief Report: Depression, Substance Use, and Factors Associated With Sexual Risk Behaviors Among Adults Living With HIV in the Asia-Pacific Region.
    J Acquir Immune Defic Syndr. 2024;96:421-428.
    PubMed     Abstract available


  228. MISTRI P, Tomescu S, Bokolo S, De Nooy A, et al
    Evaluation of four interventions using behavioural economics insights to increase demand for voluntary medical male circumcision in South Africa through the MoyaApp: A quasi-experimental study.
    J Acquir Immune Defic Syndr. 2024 Aug 9. doi: 10.1097/QAI.0000000000003504.
    PubMed     Abstract available


  229. LANG R, Coburn SB, Gill MJ, Grossman J, et al
    THE ASSOCIATION OF ANEMIA WITH SURVIVAL AMONG PEOPLE WITH HIV FOLLOWING ANTIRETROVIRAL INITIATION IN THE NA-ACCORD 2007-2016.
    J Acquir Immune Defic Syndr. 2024 Aug 9. doi: 10.1097/QAI.0000000000003502.
    PubMed     Abstract available


  230. LUC CM, Max B, Perez S, Herrera K, et al
    Acceptability of Long-Acting Cabotegravir + Rilpivirine in a Large, Urban, Ambulatory HIV Clinic.
    J Acquir Immune Defic Syndr. 2024 Aug 5. doi: 10.1097/QAI.0000000000003500.
    PubMed     Abstract available


  231. LIPPMAN SA, Grignon JS, Ditshwane B, West RL, et al
    Results of the Sukuma Ndoda ("Stand up, Man") HIV Self-Screening and Assisted Linkage to Care Project in Johannesburg: A Quasi-Experimental Pre-Post Evaluation.
    J Acquir Immune Defic Syndr. 2024;96:367-375.
    PubMed     Abstract available


  232. GARRETT N, Dintwe O, Monaco CL, Jones M, et al
    Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.
    J Acquir Immune Defic Syndr. 2024;96:350-360.
    PubMed     Abstract available


  233. HALLARN J, Scheim AI, Bauer GR
    Pre-exposure Prophylaxis Awareness and Use Among Transgender and Nonbinary Individuals in Canada.
    J Acquir Immune Defic Syndr. 2024;96:341-349.
    PubMed     Abstract available


  234. ROHR JK, Manne-Goehler J, Gomez-Olive FX, Kahn K, et al
    The HIV Care Cascade for Older Adults in Rural South Africa: A Longitudinal Cohort Study (2014-2019).
    J Acquir Immune Defic Syndr. 2024;96:334-340.
    PubMed     Abstract available


  235. ROSEN AD, Javanbakht M, Shoptaw SJ, Seamans MJ, et al
    Associations of Sleep Deficiency With Sexual Risk Behaviors and HIV Treatment Outcomes Among Men Who Have Sex With Men Living With or at High Risk of Acquiring HIV.
    J Acquir Immune Defic Syndr. 2024;96:326-333.
    PubMed     Abstract available


  236. TSENG AS, Mugwanya KK, Szpiro AA, van Heerden A, et al
    Estimating the Effect of COVID-19 Pandemic Restrictions on Self-reported Antiretroviral Therapy Use and Late Refill Visits Among People Living With HIV in Rural South Africa.
    J Acquir Immune Defic Syndr. 2024;96:318-325.
    PubMed     Abstract available



  237. Effectiveness of PrEPTECH: Findings From a 180-Day Randomized Controlled Trial of a Pre-Exposure Prophylaxis Telehealth Intervention: Erratum.
    J Acquir Immune Defic Syndr. 2024;96:410.
    PubMed    


  238. MORRISON S, Batting J, Wanga V, Beesham I, et al
    True and false positive HIV point of care test results in a prospective multinational study of at-risk African women: implications for large-scale repeat HIV testing in HIV prevention programs.
    J Acquir Immune Defic Syndr. 2024 Aug 1. doi: 10.1097/QAI.0000000000003497.
    PubMed     Abstract available


  239. FOLEY JD, Bernier LB, Ngo L, Batchelder AW, et al
    Evaluating the Efficacy of Psycho-Behavioral Interventions for Cardiovascular Risk among People Living with HIV: A Systematic Review and Meta-Synthesis of Randomized Controlled Trials.
    J Acquir Immune Defic Syndr. 2024;96:399-409.
    PubMed     Abstract available


  240. BISHOP MD, Korutaro V, Boyce CL, Beck IA, et al
    Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial.
    J Acquir Immune Defic Syndr. 2024;96:385-392.
    PubMed     Abstract available


  241. NEARY J, Njuguna I, Wagner AD, Richardson BA, et al
    Brief Report: Group-Based Trajectory Modeling to Determine Long-Term HIV Viral Load Trends Among Children With HIV in Kenya.
    J Acquir Immune Defic Syndr. 2024;96:311-317.
    PubMed     Abstract available


  242. TUKEI VJ, Machekano R, Tchounga BK, Khumalo PN, et al
    Follow-up Outcomes of Children, Adolescents and Young People on Darunavir-Based Third-line Antiretroviral Therapy - Observational Cohort from Nine African Countries.
    J Acquir Immune Defic Syndr. 2024 Aug 1. doi: 10.1097/QAI.0000000000003498.
    PubMed     Abstract available


  243. COBURN SB, Pimentel N, Leyden W, Kitahata M, et al
    Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV.
    J Acquir Immune Defic Syndr. 2024;96:393-398.
    PubMed     Abstract available


    July 2024
  244. LEONG TD, Nel J, Jamieson L, Osih R, et al
    A review and economic analysis of the dapivirine vaginal ring as HIV pre-exposure prophylaxis for women, to inform South African public-sector guidelines.
    J Acquir Immune Defic Syndr. 2024 Jul 25. doi: 10.1097/QAI.0000000000003496.
    PubMed     Abstract available


  245. SINGOGO E, Weir SS, Kudowa E, Chagomerana M, et al
    Characterising HIV acquisition risk, treatment gaps and populations reached through venue-based outreach and clinical services in Blantyre, Malawi: findings from a district-wide CLOVE Study.
    J Acquir Immune Defic Syndr. 2024 Jul 18. doi: 10.1097/QAI.0000000000003493.
    PubMed     Abstract available


  246. MCCRIMMON T, Collins LF, Pereyra M, Platamone C, et al
    Likelihood of Trying Long-Acting Injectable Antiretroviral Therapy Among Women With HIV in Nine Sites Across the United States.
    J Acquir Immune Defic Syndr. 2024;96:e23-e27.
    PubMed    


  247. OYUGA R, Amadi E, Blanco N, Ndaga A, et al
    Effects of Multimonth Dispensing on Viral Suppression and Continuity in Treatment Among Children Living With HIV Aged 2-9 Years: A Cohort Study in Western Kenya.
    J Acquir Immune Defic Syndr. 2024;96:290-298.
    PubMed     Abstract available


  248. CALABRESE SK, Zaheer MA, Flores JJ, Kalwicz DA, et al
    Messaging About HIV Transmission Risk When Viral Load Is Undetectable: Reactions and Perceived Accuracy Among US Sexual Minority Men.
    J Acquir Immune Defic Syndr. 2024;96:270-279.
    PubMed     Abstract available


  249. AUDET CM, Graves E, Shepherd BE, Prigmore HL, et al
    Partner-Based HIV Treatment for Seroconcordant Couples Attending Antenatal and Postnatal Care in Rural Mozambique: A Cluster Randomized Controlled Trial.
    J Acquir Immune Defic Syndr. 2024;96:259-269.
    PubMed     Abstract available


  250. VITRUK O, Ihnatiuk AP, Kazanzhy AP, Shvab M, et al
    Uptake and Persistent Use of HIV Preexposure Prophylaxis Among Key Populations: Results From Ukraine's Scaled National Preexposure Prophylaxis Program.
    J Acquir Immune Defic Syndr. 2024;96:241-249.
    PubMed     Abstract available


  251. BAKOYANNIS G, Elul B, Wools-Kaloustian KK, Brown S, et al
    Modeling the HIV Cascade of Care Using Routinely Collected Clinical Data to Guide Programmatic Interventions and Policy Decisions.
    J Acquir Immune Defic Syndr. 2024;96:223-230.
    PubMed     Abstract available


  252. PETERS BA, Hanna DB, Xue X, Weber K, et al
    Menopause and Estrogen Associations With Gut Barrier, Microbial Translocation, and Immune Activation Biomarkers in Women With and Without HIV.
    J Acquir Immune Defic Syndr. 2024;96:214-222.
    PubMed     Abstract available


  253. CHOI J, May SB, Dang BN, Markham C, et al
    Acceptability of a Future HIV Vaccine: A Rapid Scoping Review.
    J Acquir Immune Defic Syndr. 2024;96:197-207.
    PubMed     Abstract available


    June 2024
  254. DIRAJLAL-FARGO S, Sattar A, Strah M, Karungi C, et al
    Immune activation is associated with neurocognitive performance in Ugandan Adolescents living with HIV.
    J Acquir Immune Defic Syndr. 2024 Jun 21. doi: 10.1097/QAI.0000000000003483.
    PubMed     Abstract available



  255. Short-term Outcomes From a Cluster Randomized Evaluation of Adherence Clubs as Part of Differentiated HIV Care in South Africa: Retraction.
    J Acquir Immune Defic Syndr. 2024;96:e14.
    PubMed    



  256. Perception and Emotional Experiences of Infant Feeding Among Women Living With HIV in a High-Income Setting: A Longitudinal Mixed Methods Study: Erratum.
    J Acquir Immune Defic Syndr. 2024;96:e12-e13.
    PubMed    


  257. IANNONE V, Ciccullo A, Moschese D, Giacomelli A, et al
    Treatment Experienced People Living With HIV switching to DOR/3TC/TDF in Outpatient Setting: Real-World Data on Tolerability and Cost Savings From an Italian Multicenter Cohort.
    J Acquir Immune Defic Syndr. 2024;96:e10-e11.
    PubMed    


  258. JI C, Chen L, Kaypaghian M
    Effects of Combination of Ethanol With Ritonavir, Lopinavir or Darunavir on Expression and Localization of the ER-Associated Set Protein and Infection of HIV-1 Pseudovirus in Primary Human Cells.
    J Acquir Immune Defic Syndr. 2024;96:e6-e10.
    PubMed    


  259. BENNETT CL, Saxena M, Boothroyd D, Mahmoud-Werthmann S, et al
    Association Between Social Vulnerability and US HIV Priority Jurisdictions.
    J Acquir Immune Defic Syndr. 2024;96:e4-e6.
    PubMed    


  260. ZHOU S, Cluver L, Knight L, Edun O, et al
    Longitudinal Trajectories of Antiretroviral Treatment Adherence and Associations With Durable Viral Suppression Among Adolescents Living With HIV in South Africa.
    J Acquir Immune Defic Syndr. 2024;96:171-179.
    PubMed     Abstract available


  261. WHITE DAE, Godoy A, Jewett M, Burns M, et al
    Outcomes of an Emergency Department Program to Identify and Link Patients at Increased Risk for Acquiring HIV Infection to Outpatient HIV Prevention Services: The HIV PreventED Program.
    J Acquir Immune Defic Syndr. 2024;96:147-155.
    PubMed     Abstract available


  262. ROSENTHAL M, Patterson W, Rajulu DT
    Missed Opportunities: Characteristics of People Who Received a Concurrent HIV/AIDS Diagnosis in New York State From 2016 to 2021.
    J Acquir Immune Defic Syndr. 2024;96:130-135.
    PubMed     Abstract available


  263. BECKER M, Mishra S, Bhattacharjee P, Musyoki H, et al
    Differential Burden of HIV Among Adolescent Girls and Young Women by Places Associated With Sex Work: An Observational Study in Mombasa, Kenya.
    J Acquir Immune Defic Syndr. 2024;96:121-129.
    PubMed     Abstract available



  264. Short-Term Outcomes From a Cluster Randomized Evaluation of Adherence Clubs as Part of Differentiated HIV Care in South Africa [RETRACTED].
    J Acquir Immune Defic Syndr. 2024;96:e15-e22.
    PubMed    


    May 2024

  265. Time to Treatment Initiation and HIV Viral Suppression in People Diagnosed With HIV-1 During COVID-19 Pandemic in Ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study): Erratum.
    J Acquir Immune Defic Syndr. 2024;96:e3.
    PubMed    


  266. RAMBIKI E, Rambiki K, Khalani J, Huwa J, et al
    Letters to the Editor Low Rates of Side Effects in Paclitaxel Chemotherapy for Kaposi Sarcoma and Feasibility of Treatment in Outpatient ART Clinic Settings in Malawi.
    J Acquir Immune Defic Syndr. 2024;96:e1-e2.
    PubMed    


    April 2024
  267. DORWARD J, Sookrajh Y, Lessells R, Bulo E, et al
    Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;95:e8-e11.
    PubMed    


  268. KABAMI J, Koss CA, Sunday H, Biira E, et al
    Randomized Trial of Dynamic Choice HIV Prevention at Antenatal and Postnatal Care Clinics in Rural Uganda and Kenya.
    J Acquir Immune Defic Syndr. 2024;95:447-455.
    PubMed     Abstract available


  269. YOUNGUI BT, Atwine D, Otai D, Vasiliu A, et al
    Integration of HIV Testing in a Community Intervention for Tuberculosis Screening Among Household Contacts of Patients with Tuberculosis in Cameroon and Uganda.
    J Acquir Immune Defic Syndr. 2024;95:431-438.
    PubMed     Abstract available


  270. SHADE SB, Gutin SA, Agnew E, Grignon JS, et al
    Cost Analysis of Short Messaging Service and Peer Navigator Interventions for Linking and Retaining Adults Recently Diagnosed With HIV in Care in South Africa.
    J Acquir Immune Defic Syndr. 2024;95:417-423.
    PubMed     Abstract available


  271. FU W, McClymont E, Av-Gay G, Dorling M, et al
    Retrospective Cohort Study on the Impact of the COVID-19 Pandemic on Pregnancy Outcomes for Women Living With HIV in British Columbia.
    J Acquir Immune Defic Syndr. 2024;95:411-416.
    PubMed     Abstract available


  272. MOAWAD MHED, Mohamed Shalaby MM, Hamouda E, Mahfouz A, et al
    Risk of Stroke Among HIV Patients: A Systematic Review and Meta-analysis of Global Studies and Associated Comorbidities.
    J Acquir Immune Defic Syndr. 2024;95:399-410.
    PubMed     Abstract available


  273. ERENRICH RK, Braun RA, Torres-Mendoza DM, Stevenson OL, et al
    Effectiveness of PrEPTECH: Findings From a 180-Day Randomized Controlled Trial of a Pre-Exposure Prophylaxis Telehealth Intervention.
    J Acquir Immune Defic Syndr. 2024;95:463-469.
    PubMed     Abstract available


  274. MUTETWA T, Liu Y, Silvera R, Evans M, et al
    Host Nuclear Genome Copy Number Variations Identify High-Risk Anal Precancers in People Living with HIV.
    J Acquir Immune Defic Syndr. 2024 Apr 15. doi: 10.1097/QAI.0000000000003409.
    PubMed     Abstract available


  275. ERLY S, Menza TW, Granillo L, Navejas M, et al
    Impact of COVID-19 on People Living with HIV: Data from Five Medical Monitoring Project Sites, 2020-2022.
    J Acquir Immune Defic Syndr. 2024 Apr 2. doi: 10.1097/QAI.0000000000003403.
    PubMed     Abstract available


  276. KENNEDY CE, Yeh PT, Verster A, Luhmann N, et al
    Do Peer Navigators Improve Initiation and Retention in HIV/VH/STI Treatment Programs for People From Key Populations? A Systematic Review of Effectiveness, Values and Preferences, and Cost.
    J Acquir Immune Defic Syndr. 2024;95:305-312.
    PubMed     Abstract available


  277. VOLK JE, Leyden WA, Lea AN, Lee C, et al
    Using Electronic Health Records to Improve HIV Preexposure Prophylaxis Care: A Randomized Trial.
    J Acquir Immune Defic Syndr. 2024;95:362-369.
    PubMed     Abstract available


  278. FRANCE AM, Panneer N, Farnham PG, Oster AM, et al
    Simulation of Full HIV Cluster Networks in a Nationally Representative Model Indicates Intervention Opportunities.
    J Acquir Immune Defic Syndr. 2024;95:355-361.
    PubMed     Abstract available


  279. LOGAN NZ, Kilmarx PH, Rolle I, Patel HK, et al
    Brief Report: Self-Reported HIV-Positive Status but Subsequent HIV-Negative Test Results in Population-Based HIV Impact Assessment Survey Participants-11 Sub-Saharan African Countries, 2015-2018.
    J Acquir Immune Defic Syndr. 2024;95:313-317.
    PubMed     Abstract available


    March 2024
  280. HICKEY MD, Grochowski J, Mayorga-Munoz F, Oskarsson J, et al
    Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People with HIV Who Are Virally Unsuppressed.
    J Acquir Immune Defic Syndr. 2024 Mar 27. doi: 10.1097/QAI.0000000000003421.
    PubMed     Abstract available


  281. LINNEMAYR S, Wagner Z, Saya UY, Stecher C, et al
    Behavioral economic incentives to support HIV care: Results from a randomized controlled trial in Uganda.
    J Acquir Immune Defic Syndr. 2024 Mar 27. doi: 10.1097/QAI.0000000000003420.
    PubMed     Abstract available


  282. QIAN Y, Zhang P, Wang L, Suo J, et al
    The association of intraocular efavirenz concentrations and HIV-1 viral load among persons with HIV.
    J Acquir Immune Defic Syndr. 2024 Mar 25. doi: 10.1097/QAI.0000000000003426.
    PubMed     Abstract available


  283. BUNTING SR, Feinstein BA, Vidyasagar N, Sheth NK, et al
    Psychiatry and Family Medicine Residents' Likelihood of Prescribing HIV Pre-Exposure Prophylaxis (PrEP) to Patients with Mental Illness and HIV Vulnerability.
    J Acquir Immune Defic Syndr. 2024 Mar 25. doi: 10.1097/QAI.0000000000003423.
    PubMed     Abstract available


  284. PATEL D, Williams WO, Wright C, Essuon A, et al
    CDC-Funded HIV Testing and Undiagnosed HIV Infection in Ending the HIV Epidemic in the U.S. Jurisdictions.
    J Acquir Immune Defic Syndr. 2024 Mar 23. doi: 10.1097/QAI.0000000000003424.
    PubMed     Abstract available


  285. WEISER J, Tie Y, Crim SM, Riedel DJ, et al
    Do HIV Care Outcomes Differ by Provider Type?
    J Acquir Immune Defic Syndr. 2024 Mar 7. doi: 10.1097/QAI.0000000000003410.
    PubMed     Abstract available


  286. MADLALA HP, Myer L, Geffen H, Rusch J, et al
    Inflammatory markers in pregnancy are associated with postpartum weight in South African women living with HIV on antiretroviral therapy.
    J Acquir Immune Defic Syndr. 2024 Mar 4. doi: 10.1097/QAI.0000000000003406.
    PubMed     Abstract available


  287. NUNEZ I, Ceballos-Liceaga SE, Torre A, Garcia-Rodriguez G, et al
    Clinical features and outcomes of mpox in people with and without HIV: a national comparative study.
    J Acquir Immune Defic Syndr. 2024 Mar 4. doi: 10.1097/QAI.0000000000003407.
    PubMed     Abstract available


  288. HANLEY S, Moodley D, Naidoo M, Brummel SS, et al
    THE IMPACT OF REGULAR SCREENING AND LIFESTYLE MODIFICATION ON CARDIOVASCULAR DISEASE RISK FACTORS IN SOUTH AFRICAN WOMEN LIVING WITH HIV.
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003387.
    PubMed     Abstract available


  289. OBOHO IK, Esber AL, Dear N, Paulin HN, et al
    Advanced HIV Disease in East Africa and Nigeria, in The African Cohort Study (AFRICOS).
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003392.
    PubMed     Abstract available


  290. BEN FARHAT J, TiendrebeogoMD T, Malateste K, Poda A, et al
    Effects of the Covid-19 pandemic on ART initiation and access to HIV viral load monitoring in adults living with HIV in West Africa: a regression discontinuity analysis.
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003404.
    PubMed     Abstract available


  291. TANAKA T, Oshima K, Kawano K, Tashiro M, et al
    Nationwide Longitudinal Annual Survey of HIV/AIDS Referral Hospitals in Japan From 1999-2021: Trend in Non-AIDS-Defining Cancers Among HIV-1-Infected Individuals.
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003389.
    PubMed     Abstract available


  292. CALZA L, Giglia M, Viale P
    Relationship Between Vitamin D Deficiency and Nonalcoholic Fatty Liver Disease in Patients With HIV-1 Infection.
    J Acquir Immune Defic Syndr. 2024;95:e5-e7.
    PubMed    


  293. MCCRARY AW, Hung F, Foster MC, Koech M, et al
    Letter to the Editor: Cardiac Dysfunction Among Youth With Perinatal HIV Acquisition and Exposure.
    J Acquir Immune Defic Syndr. 2024;95:e2-e4.
    PubMed    


  294. NABUKALU D, Yiannoutsos CT, Semeere A, Musick BS, et al
    Mortality Among HIV-Infected Adults on Antiretroviral Therapy in Southern Uganda.
    J Acquir Immune Defic Syndr. 2024;95:268-274.
    PubMed     Abstract available


  295. VAN HEERDEN JK, Meintjes G, Barr D, Zhao Y, et al
    Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;95:260-267.
    PubMed     Abstract available


  296. NGUMBAU NM, Neary J, Wagner AD, Abuna F, et al
    Cofactors of Partner HIV Self-testing and Oral PrEP Acceptance Among Pregnant Women at High Risk of HIV in Kenya.
    J Acquir Immune Defic Syndr. 2024;95:238-245.
    PubMed     Abstract available


    February 2024
  297. OPSTEEN S, Fram T, Files JK, Levitan EB, et al
    Impact of Chronic HIV Infection on Acute Immune Responses to SARS-CoV-2.
    J Acquir Immune Defic Syndr. 2024 Feb 8. doi: 10.1097/QAI.0000000000003399.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.